1887

Abstract

Equine sarcoids are fibrosarcoma-like skin tumours with a prevalence of approximately 1–2 %. Strong evidence exists for a causative role of bovine papillomavirus (BPV) type 1 or type 2 in the development of sarcoids. No effective treatment of equine sarcoid is available and after surgical excision relapse of the tumours is very frequent. We developed chimeric virus-like particles (CVLPs) of BPV 1 L1–E7 for the immunotherapy of equine sarcoid. In a phase I clinical trial 12 horses suffering from equine sarcoid with an average number of more than 22 tumours per animal were vaccinated in a dose-escalation setting. The animals were followed-up for 63 days, eight of the twelve horses were followed-up for more than a year and side-effects, humoral immune responses and tumour appearance were recorded. BPV DNA was detected in tumours of 11 cases. CVLPs were well tolerated in all dose groups, a robust anti-L1 antibody response was induced in all but one of the horses. Anti-E7 antibodies were detected in five of the 12 animals at low titres. Two animals showed a clear improvement of the clinical status after treatment, i.e. the number of the tumours per horse was reduced. In another horse regression of five sarcoids was observed; three of them relapsed during the study. Two animals showed tumour regression as well as growth of new sarcoids. In two horses the clinical status remained unchanged, in another two horses growth of existing tumours or growth of additional tumours was observed. The remaining three animals showed simultaneously regression and growth of existing tumours. Neither the humoral immune responses nor the observed effects on the tumours was correlated with the dose group.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.83266-0
2008-01-01
2020-01-28
Loading full text...

Full text loading...

/deliver/fulltext/jgv/89/1/138.html?itemId=/content/journal/jgv/10.1099/vir.0.83266-0&mimeType=html&fmt=ahah

References

  1. Amtmann, E., Müller, H. & Sauer, G. ( 1980; ). Equine connective tissue tumors contain unintegrated bovine papilloma virus DNA. J Virol 35, 962–964.
    [Google Scholar]
  2. Breitburd, F., Salmon, J. & Orth, G. ( 1997; ). The rabbit viral skin papillomas and carcinomas: a model for the immunogenetics of HPV-associated carcinogenesis. Clin Dermatol 15, 237–247.[CrossRef]
    [Google Scholar]
  3. Buck, C. B., Pastrana, D. V., Lowy, D. R. & Schiller, J. T. ( 2005; ). Generation of HPV pseudovirions using transfection and their use in neutralization assays. Methods Mol Med 119, 445–462.
    [Google Scholar]
  4. Campo, M. S. ( 1994; ). Vaccination against papillomavirus in cattle. Curr Top Microbiol Immunol 186, 255–266.
    [Google Scholar]
  5. Campo, M. S. ( 1997; ). Bovine papillomavirus and cancer. Vet J 154, 175–188.[CrossRef]
    [Google Scholar]
  6. Campo, M. S. ( 2002; ). Animal models of papillomavirus pathogenesis. Virus Res 89, 249–261.[CrossRef]
    [Google Scholar]
  7. Carr, E. A., Theon, A. P., Madewell, B. R., Hitchcock, M. E., Schlegel, R. & Schiller, J. T. ( 2001; ). Expression of a transforming gene (E5) of bovine papillomavirus in sarcoids obtained from horses. Am J Vet Res 62, 1212–1217.[CrossRef]
    [Google Scholar]
  8. Chambers, G., Ellsmore, V. A., O'Brien, P. M., Reid, S. W., Love, S., Campo, M. S. & Nasir, L. ( 2003; ). Association of bovine papillomavirus with the equine sarcoid. J Gen Virol 84, 1055–1062.[CrossRef]
    [Google Scholar]
  9. de Villiers, E. M., Fauquet, C., Broker, T. R., Bernard, H. U. & zur Hausen, H. ( 2004; ). Classification of papillomaviruses. Virology 324, 17–27.[CrossRef]
    [Google Scholar]
  10. Garcea, R. L. & Gissmann, L. ( 2004; ). Virus-like particles as vaccines and vessels for the delivery of small molecules. Curr Opin Biotechnol 15, 513–517.[CrossRef]
    [Google Scholar]
  11. Gissmann, L., Osen, W., Müller, M. & Jochmus, I. ( 2001; ). Therapeutic vaccines for human papillomaviruses. Intervirology 44, 167–175.[CrossRef]
    [Google Scholar]
  12. Goodrich, L., Gerber, H., Marti, E. & Antczak, D. F. ( 1998; ). Equine sarcoids. Vet Clin North Am Equine Pract 14, 607–623. (vii).
    [Google Scholar]
  13. Greenstone, H. L., Nieland, J. D., de Visser, K. E., De Bruijn, M. L., Kirnbauer, R., Roden, R. B., Lowy, D. R., Kast, W. M. & Schiller, J. T. ( 1998; ). Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc Natl Acad Sci U S A 95, 1800–1805.[CrossRef]
    [Google Scholar]
  14. Kaufmann, A. M., Nieland, J., Schinz, M., Nonn, M., Gabelsberger, J., Meissner, H., Müller, R. T., Jochmus, I., Gissmann, L. & other authors ( 2001; ). HPV16 L1E7 chimeric virus-like particles induce specific HLA-restricted T cells in humans after in vitro vaccination. Int J Cancer 92, 285–293.[CrossRef]
    [Google Scholar]
  15. Kaufmann, A. M., Nieland, J. D., Jochmus, I., Baur, S., Friese, K., Gabelsberger, J., Gieseking, F., Gissmann, L., Glasschroder, B. & other authors ( 2007; ). Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3). Int J Cancer 121, 2794–2800.[CrossRef]
    [Google Scholar]
  16. Kirnbauer, R. ( 1996; ). Papillomavirus-like particles for serology and vaccine development. Intervirology 39, 54–61.
    [Google Scholar]
  17. Knottenbelt, D. C. ( 2005; ). A suggested clinical classification for the equine sarcoid. Clin Tech Equine Pract 4, 278–295.[CrossRef]
    [Google Scholar]
  18. Lancaster, W. D., Olson, C. & Meinke, W. ( 1977; ). Bovine papilloma virus: presence of virus-specific DNA sequences in naturally occurring equine tumors. Proc Natl Acad Sci U S A 74, 524–528.[CrossRef]
    [Google Scholar]
  19. Lazary, S., Gerber, H., Glatt, P. A. & Straub, R. ( 1985; ). Equine leucocyte antigens in sarcoid-affected horses. Equine Vet J 17, 283–286.[CrossRef]
    [Google Scholar]
  20. Lowy, D. R. & Frazer, I. H. ( 2003; ). Chapter 16: Prophylactic human papillomavirus vaccines. J Natl Cancer Inst Monogr 31, 111–116.
    [Google Scholar]
  21. Lowy, D. & Howley, P. ( 2002; ). Papillomaviruses. In Fields Virology, 4th edn, pp. 2231–2264. Edited by D. M. Knipe & P. M. Howley. Philadelphia, PA: Lippincott Williams and Willkins.
  22. Müller, H. ( 1991; ). Papillomatosis of cattle and its relationship to equine sarcoid. Tierarztl Prax 19, 39–43.
    [Google Scholar]
  23. Müller, M., Viscidi, R. P., Sun, Y., Guerrero, E., Hill, P. M., Shah, F., Bosch, F. X., Munoz, N., Gissmann, L. & other authors ( 1992; ). Antibodies to HPV-16 E6 and E7 proteins as markers for HPV-16-associated invasive cervical cancer. Virology 187, 508–514.[CrossRef]
    [Google Scholar]
  24. Müller, M., Zhou, J., Reed, T. D., Rittmüller, C., Burger, A., Gabelsberger, J., Braspenning, J. & Gissmann, L. ( 1997; ). Chimeric papillomavirus-like particles. Virology 234, 93–111.[CrossRef]
    [Google Scholar]
  25. Nasir, L. & Reid, S. W. ( 1999; ). Bovine papillomaviral gene expression in equine sarcoid tumours. Virus Res 61, 171–175.[CrossRef]
    [Google Scholar]
  26. Nicholls, P. K. & Stanley, M. A. ( 2000; ). The immunology of animal papillomaviruses. Vet Immunol Immunopathol 73, 101–127.[CrossRef]
    [Google Scholar]
  27. Nieland, J. D., Da Silva, D. M., Velders, M. P., de Visser, K. E., Schiller, J. T., Müller, M. & Kast, W. M. ( 1999; ). Chimeric papillomavirus virus-like particles induce a murine self-antigen-specific protective and therapeutic antitumor immune response. J Cell Biochem 73, 145–152.[CrossRef]
    [Google Scholar]
  28. Nixon, C., Chambers, G., Ellsmore, V., Campo, M. S., Burr, P., Argyle, D. J., Reid, S. W. & Nasir, L. ( 2005; ). Expression of cell cycle associated proteins cyclin A, CDK-2, p27kip1 and p53 in equine sarcoids. Cancer Lett 221, 237–245.[CrossRef]
    [Google Scholar]
  29. Ohlschlager, P., Osen, W., Dell, K., Faath, S., Garcea, R. L., Jochmus, I., Müller, M., Pawlita, M., Schäfer, K. & other authors ( 2003; ). Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice. J Virol 77, 4635–4645.[CrossRef]
    [Google Scholar]
  30. Pastrana, D. V., Buck, C. B., Pang, Y. Y., Thompson, C. D., Castle, P. E., FitzGerald, P. C., Kruger Kjaer, S., Lowy, D. R. & Schiller, J. T. ( 2004; ). Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 321, 205–216.[CrossRef]
    [Google Scholar]
  31. Ragland, K. W. L., Keown, G. F. H. & Spencer, G. R. ( 1970; ). Equine sarcoids. Equine Vet J 2, 2–11.[CrossRef]
    [Google Scholar]
  32. Rudolf, M. P., Fausch, S. C., Da Silva, D. M. & Kast, W. M. ( 2001; ). Human dendritic cells are activated by chimeric human papillomavirus type-16 virus-like particles and induce epitope-specific human T cell responses in vitro. J Immunol 166, 5917–5924.[CrossRef]
    [Google Scholar]
  33. Schäfer, K., Müller, M., Faath, S., Henn, A., Osen, W., Zentgraf, H., Benner, A., Gissmann, L. & Jochmus, I. ( 1999; ). Immune response to human papillomavirus 16 L1E7 chimeric virus-like particles: induction of cytotoxic T cells and specific tumor protection. Int J Cancer 81, 881–888.[CrossRef]
    [Google Scholar]
  34. Schiller, J. T. & Lowy, D. R. ( 2001; ). Papillomavirus-like particle vaccines. J Natl Cancer Inst Monogr 50–54.
    [Google Scholar]
  35. Schreckenberger, C. & Kaufmann, A. M. ( 2004; ). Vaccination strategies for the treatment and prevention of cervical cancer. Curr Opin Oncol 16, 485–491.[CrossRef]
    [Google Scholar]
  36. Sehr, P., Zumbach, K. & Pawlita, M. ( 2001; ). A generic capture ELISA for recombinant proteins fused to glutathione S-transferase: validation for HPV serology. J Immunol Methods 253, 153–162.[CrossRef]
    [Google Scholar]
  37. Thönes, N. & Müller, M. ( 2007; ). Oral immunization with different assembly forms of the HPV 16 major capsid protein L1 induces neutralizing antibodies and cytotoxic T-lymphocytes. Virology 369, 375–388.[CrossRef]
    [Google Scholar]
  38. Yuan, Z., Philbey, A. W., Gault, E. A., Campo, M. S. & Nasir, L. ( 2007; ). Detection of bovine papillomavirus type 1 genomes and viral gene expression in equine inflammatory skin conditions. Virus Res 124, 245–249.[CrossRef]
    [Google Scholar]
  39. Zur Hausen, H. ( 2006; ). Perspectives of contemporary papillomavirus research. Vaccine 24 (Suppl. 3), iii–iv.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.83266-0
Loading
/content/journal/jgv/10.1099/vir.0.83266-0
Loading

Data & Media loading...

Most cited articles

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error